SBF’s Lawyers Raise Concerns About Access to Medication
Lawyers representing Sam Bankman-Fried have expressed worries once again about their client’s ability to access Adderall, a medication prescribed for his ADHD. They are requesting that Bankman-Fried be given additional Adderall during his hearings, as they believe his concentration and ability to testify in his defense may be impacted without the medication.
SBF’s Lawyers Petition the Court for More Medication
In a letter of motion submitted by Bankman-Fried’s legal team, it was revealed that he has been facing a shortage of Adderall during trial hours. The motion states that without access to Adderall, Bankman-Fried has been unable to concentrate at his usual level and fears that he won’t be able to actively participate in presenting his defense.
Subscribe to our Social Media for Exclusive Crypto News and Insights 24/7!
According to previous court filings, Bankman-Fried currently receives only one dose of Adderall early in the morning, which wears off before his trial begins. He typically takes 10 mg of Adderall three to four times daily.
Sam Bankman-Fried’s Struggles with Adderall Access
Bankman-Fried has faced ongoing challenges in accessing Adderall. While he was in a Brooklyn jail after his bail was revoked, there was a dispute regarding his access to the medication. Although a motion was approved to grant him “uninterrupted access” to his prescription, his lawyers reported that he had not received it for 11 days.
In addition to Adderall, Bankman-Fried’s supply of Emsam, a transdermal patch used for depression treatment, was also limited and running low. His lawyers are now planning to administer an extended-release pill on Monday as a potential solution. However, they are still determining its availability within the Bureau of Prisons and its effectiveness for Bankman-Fried.
Hot Take: Concerns Raised About Sam Bankman-Fried’s Access to Medication
Sam Bankman-Fried’s legal team has once again expressed concerns about their client’s access to Adderall during his trial hearings. They argue that without the medication, Bankman-Fried may struggle to concentrate and effectively participate in presenting his defense. This is not the first time Bankman-Fried has faced challenges in accessing Adderall, as previous disputes arose while he was in jail. His lawyers are now seeking a solution by administering an extended-release pill and are exploring its availability within the Bureau of Prisons. The outcome of this issue may have implications for Bankman-Fried’s ability to fully engage in his legal proceedings.
